covax + inactivated influenza vaccine (quadrivalent)

This is a **combination vaccine product** containing Covax (presumed based on name, but specifics unknown from available sources) and a **quadrivalent inactivated influenza vaccine (IIV4)**. The quadrivalent inactivated influenza vaccine (IIV4) is formulated to provide active immunization against influenza disease caused by two Influenza A subtypes and two type B viruses. These vaccines typically contain 15 mcg of hemagglutinin (HA) per strain, with a total of four strains for quadrivalent formulations, and are standardized for seasonal recommendations. The mechanism of action is induction of an immune response to viral antigens, promoting antibody-mediated protection against influenza infection. Quadrivalent IIVs are produced through inactivation of influenza viruses grown in hens’ eggs, with antigens purified for use. These products are administered intramuscularly and are recommended for annual immunization in eligible age groups, with some variations on age indications across brands. Developer and manufacturer information for Covax is unspecified from available data; multiple companies manufacture quadrivalent inactivated influenza vaccines, including Seqirus, Sanofi, and GSK.